CN106723022A - 一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 - Google Patents
一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 Download PDFInfo
- Publication number
- CN106723022A CN106723022A CN201611068355.XA CN201611068355A CN106723022A CN 106723022 A CN106723022 A CN 106723022A CN 201611068355 A CN201611068355 A CN 201611068355A CN 106723022 A CN106723022 A CN 106723022A
- Authority
- CN
- China
- Prior art keywords
- capsule
- powder
- sika deer
- peacilomyce hepiahi
- deer velvet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003056 antler Anatomy 0.000 title claims abstract description 63
- 241000283007 Cervus nippon Species 0.000 title claims abstract description 47
- 241000894006 Bacteria Species 0.000 title claims abstract description 44
- 239000002775 capsule Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 47
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 238000005469 granulation Methods 0.000 claims abstract description 7
- 230000003179 granulation Effects 0.000 claims abstract description 7
- 238000005498 polishing Methods 0.000 claims abstract description 7
- 239000011122 softwood Substances 0.000 claims abstract description 7
- 235000020985 whole grains Nutrition 0.000 claims abstract description 7
- 238000007873 sieving Methods 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 229920001903 high density polyethylene Polymers 0.000 claims description 3
- 239000004700 high-density polyethylene Substances 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241000125175 Angelica Species 0.000 claims 4
- 210000004907 gland Anatomy 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 244000061520 Angelica archangelica Species 0.000 abstract description 11
- 230000036541 health Effects 0.000 abstract description 6
- 239000000428 dust Substances 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000012856 packing Methods 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 9
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 241000235342 Saccharomycetes Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 241000607768 Shigella Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 244000241872 Lycium chinense Species 0.000 description 4
- 235000015468 Lycium chinense Nutrition 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000697 sensory organ Anatomy 0.000 description 4
- 229910052785 arsenic Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010036941 Prostatic atrophy Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 201000006488 atrophy of prostate Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940099908 multivitamin and calcium Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法,梅花鹿茸蝙蝠蛾拟青霉菌胶囊各组份以质量份计分别如下:梅花鹿茸粉10~18份,蝙蝠蛾拟青霉菌粉40份,当归提取物12份,枸杞子提取物13份,硬脂酸镁1份。制备方法如下(1)过筛、称量;(2)混合;(3)制软材;(4)制粒;(5)干燥;(6)整粒;(7)总混;(8)胶囊填充;(9)抛光;(10)挑选、包装。本发明梅花鹿茸蝙蝠蛾拟青霉菌胶囊亦称“连天射胶囊”,是一种保健品,具有增强免疫力之功效;服用方便。其制备方法从过筛、称量直至内包装均在30万级洁净车间内进行,科学合理,卫生可靠。
Description
技术领域
本发明属于保健品制备技术领域,特别是涉及一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法。
背景技术
梅花鹿茸,又名黄毛茸、花茸,为梅花鹿的头茬二杠幼角。梅花鹿茸含有比人参更丰富的氨基酸,包括甘氨酸(glycine)、赖氨酸(lysine)、精氨酸(arginine)、天冬氨酸(asparticacid)、谷氨酸(glutamicacid)、脯氨酸(proine)、丙氨酸(alanine)、亮氨酸(leucine)等17种以上,总氨基酸含量达50%以上;梅花鹿茸也富含卵磷脂、维生素和微量元素等。鹿茸的保健作用非常高,是良好的全身强壮药。鹿茸性温而不燥,具有振奋和提高机体功能,对全身虚弱、久病之后患者,有较好的保健作用。鹿茸可以提高机体的细胞免疫和体液免疫功能,促进淋巴细胞的转化,具有免疫促进剂的作用。它能增加机体对外界的防御能力,调节体内的免疫平衡而避免疾病发生和促进创伤愈合、病体康复,从而起到强壮身体、抵抗衰老的作用。
另外,梅花鹿茸具有多方面的药理作用,包括:
(1)对神经系统的影响:鹿茸能增强副交感神经末梢的紧张性,促进恢复神经系统和改善神经、肌肉系统之功能,同时对交感神经亦有兴奋作用。
(2)对心血管系统的影响:剂量的鹿茸可降低血压,使心脏收缩振幅变小,心率减慢,外周血管扩张。中等剂量能引起心脏收缩显著增强,收缩幅度变大,心率加快,从而使心输出量增加;鹿茸特别对已疲劳的心脏作用尤为显著。
(3)对性功能的影响:鹿茸提取物既能增加血浆睾酮浓度,又能使促黄体生成素(LH)浓度增加。因此,鹿茸对青春期的性功能障碍,壮老年期的前列腺萎缩症的治疗均有效;对治疗女性更年期障碍效果良好。
(4)鹿茸的强壮作用:鹿茸精具有较强的抗疲劳作用,能增强耐寒能力,加速创伤愈合和刺激肾上腺皮质功能。故鹿茸是传统的补益药,用于强壮、补肾、益阳。
(5)对血液成分的影响:鹿茸可使血液中血红蛋白增加,因此对于大量出血者和感染症末期的患者,特别是对于老龄患者的治疗极为有效。
(6)有性激素样作用:动物试验证实,用鹿茸酊作皮下注射,几天后即见前列腺、精囊重量增加。
(7)它能兴奋离体肠管及子宫,增强肾脏的利尿功能。鹿茸对妇女儿童均有益处,它所含的钙、磷、镁等无机元素分别参与身体的钙磷和多种酶的代谢,对促进钙的吸收、骨的生长以及增强心脏、肌肉的功能都有积极的作用。尤其是镁离子,更是具有复杂的功能,是延年益寿必不可少的物质。这对妇女因宫寒不育、月经不调,小儿的发育不良,因肾气不足而引起的牙齿生长迟缓、囟门不合、骨软等,均有较好的治疗作用。
(8)其他作用:鹿茸中有些有效成分能抑制MAO-B的活性,故有抗衰老作用;鹿茸具有抗氧化作用,增强胃肠蠕动和促进分泌功能;此外,鹿茸精还能增强机体的免疫功能等。
蝙蝠蛾拟青霉菌粉是天然冬虫夏草在制药业和食品工业上的替代品。从天然冬虫夏草分离得到虫草菌丝,经发酵培养,所得菌丝体的作用与天然冬虫夏草基本相同。虫草菌丝体粉学名蝙蝠蛾拟青霉菌粉,富含腺苷、多糖等活性物质,不仅含量丰富且比例适当,有效增强人体体质,全面提高了免疫机能和抗疲劳能力。蝙蝠蛾拟青霉菌粉中含有HH2,是女性生物钟的重要成分;可促使人体的抗体分泌量增加,可激活机体的免疫活性细胞,尤其对淋巴细胞转化和巨噬细胞吞噬率有明显促进作用。蝙蝠蛾拟青霉菌粉与冬虫夏草的药理作用基本相同,能够提高肝组织SOD的含量,抑制脂质过氧化物LPO的生成,对于高脂血症、性功能低下和慢性支气管炎等病也有一定疗效。
当归具有补血和血,调经止痛,润燥滑肠、抗癌、抗老防老、免疫之功效。
枸杞子含有丰富的胡萝卜素、多种维生素和钙、铁等健康眼睛的必需营养物质,故有明目之功,俗称“明眼子”。历代医家治疗肝血不足、肾阴亏虚引起的视物昏化和夜盲症,常常使用枸杞子。
但是目前的梅花鹿茸、蝙蝠蛾拟青霉菌存在着食用不便,有效成分被人体的吸收利用率低,效果不显著等问题,如何服用梅花鹿茸、蝙蝠蛾拟青霉菌,提高梅花鹿茸和蝙蝠蛾拟青霉菌的功效,一直来没有一种行之有效的方法。因此若能充分利用梅花鹿茸、蝙蝠蛾拟青霉菌的药用功效,开发出一种以以梅花鹿茸粉、蝙蝠蛾拟青霉菌粉为主要原料,服用方便、使用效果更为显著的保健产品,无疑具有极大的市场价值。本发明人多年来潜心研究梅花鹿茸和蝙蝠蛾拟青霉菌的服用办法,以期提高其功效。
发明内容
本发明的目的在于提供一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊,以方便梅花鹿茸、蝙蝠蛾拟青霉菌的食用,并能提高梅花鹿茸和蝙蝠蛾拟青霉菌的功效。本发明同时提出了一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊的制备方法。
本发明解决技术问题所采取的技术方案是:
第一个方面,一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊,以梅花鹿茸粉、蝙蝠蛾拟青霉菌粉、当归提取物和枸杞子提取物为原料,以硬脂酸镁为辅料,各组份以质量份计分别如下:
梅花鹿茸粉 10~18份,
蝙蝠蛾拟青霉菌粉 40份,
当归提取物 12份,
枸杞子提取物 13份,
硬脂酸镁 1份。
所述梅花鹿茸蝙蝠蛾拟青霉菌胶囊中的标志性成分腺苷≥0.70%。
第二个方面,一种如第一个方面所述的梅花鹿茸蝙蝠蛾拟青霉菌胶囊的制备方法,包括以下步骤:
(1)过筛、称量:取梅花鹿茸粉、蝙蝠蛾拟青霉菌粉、当归提取物、枸杞子提取物和硬脂酸镁分别过80目筛后称量备用;75%食用酒精备用;
(2)混合:将称量好的梅花鹿茸冻干粉、蝙蝠蛾拟青霉菌粉、当归提取物和枸杞子提取物进行混合,时间15-20min,得到混合粉;
(3)制软材:将75%食用酒精均匀喷洒于混合粉中,以“手轻握成团,捏之即散”为宜;
(4)制粒:将制好的软材过20目筛制粒;
(5)干燥:温度50-60℃,水分控制在≤5%;
(6)整粒:过20目筛整粒;
(7)总混:取称量好的硬脂酸镁与上述颗粒进行混合,时间15~20min,得到混合物;
(8)胶囊填充:将总混所得混合物装入胶囊填充机,控制装量差异在±7.0%;
(9)抛光:将充填好的胶囊用抛光机抛光;
(10)挑选、包装:挑选剔除瘪囊、破囊、空壳和/或漏粉的不合格品;采用口服固体药用高密度聚乙烯瓶进行包装。
生产环境为30万级洁净车间。
称量时,各组份以质量份计分别如下:
梅花鹿茸粉 10~18份,
蝙蝠蛾拟青霉菌粉 40份,
当归提取物 12份,
枸杞子提取物 13份,
硬脂酸镁 1份。
本发明梅花鹿茸蝙蝠蛾拟青霉菌胶囊亦称“连天射胶囊”,是一种保健品,具有增强免疫力之功效;服用方便。其制备方法从过筛、称量直至内包装均在30万级洁净车间内进行,科学合理,卫生可靠。
具体实施方式
下面通过具体实施例对本发明做进一步的描述。
实施例1:
一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊。以梅花鹿茸冻干粉、蝙蝠蛾拟青霉菌粉、当归提取物和枸杞子提取物为原料,以硬脂酸镁为辅料,每粒胶囊内含400mg,其中:
梅花鹿茸冻干粉 70 mg,
蝙蝠蛾拟青霉菌粉 200 mg,
当归提取物 60 mg,
枸杞子提取物 65 mg,
硬脂酸镁 5 mg。
实施例2:
一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊的制备方法。在30万级洁净车间内进行,包括以下步骤:
(1)过筛、称量:取梅花鹿茸冻干粉、蝙蝠蛾拟青霉菌粉、当归提取物、枸杞子提取物和硬脂酸镁分别过80目筛后称量备用;75%食用酒精备用;称量时,各组份以质量份计分别如下:
梅花鹿茸冻干粉 14份,
蝙蝠蛾拟青霉菌粉 40份,
当归提取物 12份,
枸杞子提取物 13份,
硬脂酸镁 1份;
(2)混合:将称量好的梅花鹿茸冻干粉、蝙蝠蛾拟青霉菌粉、当归提取物和枸杞子提取物进行混合,时间15-20min,得到混合粉;
(3)制软材:将75%食用酒精均匀喷洒于混合粉中,以“手轻握成团,捏之即散”为宜;
(4)制粒:将制好的软材过20目筛制粒;
(5)干燥:温度50-60℃,水分控制在≤5%;
(6)整粒:过20目筛整粒;
(7)总混:取称量好的硬脂酸镁与上述颗粒进行混合,时间15-20min,得到混合物;
(8)胶囊填充:将总混所得混合物装入胶囊填充机,每粒装入混合物400mg,控制装量差异在±7.0%;
(9)抛光:将充填好的胶囊用抛光机抛光;
(10)挑选、包装:挑选剔除瘪囊、破囊、空壳和/或漏粉的不合格品;采用口服固体药用高密度聚乙烯瓶进行包装。
制备梅花鹿茸蝙蝠蛾拟青霉菌胶囊的原辅料的质量要求如下:
a.梅花鹿茸粉
感官:浅棕色粉末,本品特有的滋味,气味;
水分≤10%;
灰分≤10%;
菌落总数≤1000CFU/g;
大肠菌群≤40MPN/100g;
霉菌≤25CFU/g;
酵母菌≤25CFU/g;
致病菌(沙门氏菌、志贺氏菌、金黄色葡萄球菌、溶血性链球菌):不得检出。
b.蝙蝠蛾拟青霉菌粉
感官:棕色粉末,本品特有的滋味,气味;
腺苷≥0.22%;
水分≤10%;
灰分≤10%;
菌落总数≤1000CFU/g;
大肠菌群≤40MPN/100g;
霉菌≤25CFU/g;
酵母菌≤25CFU/g;
致病菌(沙门氏菌、志贺氏菌、金黄色葡萄球菌、溶血性链球菌):不得检出。
c.当归提取物
感官:棕色粉末,本品特有的滋味、气味;
水分≤10%;
灰分≤10%;
铅(以Pb计)≤0.5mg/kg;
砷(以As计)≤0.3mg/kg;
汞(以Hg计)≤0.1mg/kg;
六六六≤0.2mg/kg;
滴滴涕≤0.2mg/kg;
菌落总数≤1000CFU/g;
大肠菌群≤40MPN/100g;
霉菌≤25CFU/g;
酵母菌≤25CFU/g;
致病菌(沙门氏菌、志贺氏菌、金黄色葡萄球菌、溶血性链球菌):不得检出。
d.枸杞子提取物
感官:棕色粉末,本品特有的滋味、气味;
水分≤10%;
灰分≤10%;
铅(以Pb计)≤0.5mg/kg;
砷(以As计)≤0.3mg/kg;
汞(以Hg计)≤0.1mg/kg;
六六六≤0.2mg/kg;
滴滴涕≤0.2mg/kg;
菌落总数≤1000CFU/g;
大肠菌群≤40MPN/100g;
霉菌≤25CFU/g;
酵母菌≤25CFU/g;
致病菌(沙门氏菌、志贺氏菌、金黄色葡萄球菌、溶血性链球菌):不得检出。
由上述方法制得的梅花鹿茸蝙蝠蛾拟青霉菌胶囊,经测试符合下列质量指标:
a.感官要求符合下列规定:
色泽:浅棕色;
滋味、气味:具有本品固有的滋味、气味,无异味;
性状:硬胶囊,内容物为粉末;
杂质:无肉眼可见外来杂质。
b.保健功能:增强免疫力。
c.标志性成分:腺苷≥0.70g/100g。
d.理化指标符合下列规定:
水分≤9.0%;
灰分≤10.0%;
崩解时限≤60min;
铅(以Pb计)≤1.5mg/kg;
砷(以As计)≤1.0mg/kg;
汞(以Hg计)≤0.3mg/kg;
六六六≤0.2mg/kg;
滴滴涕≤0.2mg/kg。
e.微生物学指标符合下列规定:
菌落总数≤1000CFU/g;
大肠菌群≤40MPN/100g;
霉菌≤25CFU/g;
酵母菌≤25CFU/g;
致病菌(指沙门氏菌、志贺氏菌、金黄色葡萄球菌、溶血性链球菌):不得检出。
Claims (3)
1.一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊,其特征在于,以梅花鹿茸粉、蝙蝠蛾拟青霉菌粉、当归提取物和枸杞子提取物为原料,以硬脂酸镁为辅料,各组份以质量份计分别如下:
梅花鹿茸粉 10~18份,
蝙蝠蛾拟青霉菌粉 40份,
当归提取物 12份,
枸杞子提取物 13份,
硬脂酸镁 1份。
2.如权利要求1所述的梅花鹿茸蝙蝠蛾拟青霉菌胶囊,其特征在于,其中标志性成分腺苷≥0.70%。
3.一种如权利要求1所述的梅花鹿茸蝙蝠蛾拟青霉菌胶囊的制备方法,其特征在于,包括以下步骤:
(1)过筛、称量:取梅花鹿茸粉、蝙蝠蛾拟青霉菌粉、当归提取物、枸杞子提取物和硬脂酸镁分别过80目筛后称量备用;75%食用酒精备用;
(2)混合:将称量好的梅花鹿茸粉、蝙蝠蛾拟青霉菌粉、当归提取物和枸杞子提取物进行混合,时间15-20min,得到混合粉;
(3)制软材:将75%食用酒精均匀喷洒于混合粉中,以“手轻握成团,捏之即散”为宜;
(4)制粒:将制好的软材过20目筛制粒;
(5)干燥:温度50-60℃,水分控制在≤5%;
(6)整粒:过20目筛整粒;
(7)总混:取称量好的硬脂酸镁与上述颗粒进行混合,时间15~20min,得到混合物;
(8)胶囊填充:将总混所得混合物装入胶囊填充机,控制装量差异在±7.0%;
(9)抛光:将充填好的胶囊用抛光机抛光;
(10)挑选、包装:挑选剔除瘪囊、破囊、空壳和/或漏粉的不合格品;采用口服固体药用高密度聚乙烯瓶进行包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611068355.XA CN106723022A (zh) | 2016-11-29 | 2016-11-29 | 一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611068355.XA CN106723022A (zh) | 2016-11-29 | 2016-11-29 | 一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106723022A true CN106723022A (zh) | 2017-05-31 |
Family
ID=58904948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611068355.XA Pending CN106723022A (zh) | 2016-11-29 | 2016-11-29 | 一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106723022A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109077317A (zh) * | 2018-07-19 | 2018-12-25 | 深圳市博奥生物科技有限公司 | 一种番茄红素胶囊及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103211220A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种增强免疫力功能的保健食品及其制备方法 |
CN103211219A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种缓解体力疲劳的保健食品及其制备方法 |
CN104839689A (zh) * | 2015-04-21 | 2015-08-19 | 吉林大学珠海学院 | 一种健脾养胃、抗疲劳和提高免疫力作用的保健品 |
-
2016
- 2016-11-29 CN CN201611068355.XA patent/CN106723022A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103211220A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种增强免疫力功能的保健食品及其制备方法 |
CN103211219A (zh) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | 一种缓解体力疲劳的保健食品及其制备方法 |
CN104839689A (zh) * | 2015-04-21 | 2015-08-19 | 吉林大学珠海学院 | 一种健脾养胃、抗疲劳和提高免疫力作用的保健品 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109077317A (zh) * | 2018-07-19 | 2018-12-25 | 深圳市博奥生物科技有限公司 | 一种番茄红素胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102742840A (zh) | 一种玛卡虫草口含片及其制备方法 | |
CN103356751B (zh) | 增强性功能、促进男性性器官再生长的提取物组合物 | |
CN105012711B (zh) | 一种用于缓解体力疲劳和补肾壮阳的组合物及其制备方法 | |
CN101537034B (zh) | 含有玛卡的功能保健品及其制备方法 | |
CN101053621B (zh) | 一种治疗肥胖症的中药组合物及其制备方法 | |
CN104489681A (zh) | 一种具有增强免疫力功能的组合物、保健品及其制备方法 | |
AU2016201968A1 (en) | Sporoderm-broken ganoderma lucidum spore powder, honey & propolis buccal tablet and manufacturing method thereof | |
CN103099833A (zh) | 有助于缓解运动疲劳和延缓衰老的软胶囊及其制备方法 | |
KR20130056780A (ko) | 한약 농축액과 분말을 이용한 한약 조성물 | |
CN101884783B (zh) | 一种含有麦麸多肽的抗疲劳中药及其制备方法 | |
CN105770420A (zh) | 一种具有抗癌作用的中草药剂及其制备方法 | |
CN105708970B (zh) | 一种具有降血糖功能的保健食品 | |
CN105433382B (zh) | 一种玛咖组合物及其制备方法和用途 | |
CN105663204A (zh) | 一种具有提高免疫功能、抗疲劳、治疗感冒的组合物和制剂及其制备方法和用途 | |
CN104382002A (zh) | 一种缓解疲劳的玛咖片 | |
CN106417817A (zh) | 一种袋泡助眠安神茶及其制备方法 | |
CN106723022A (zh) | 一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 | |
CN102626463A (zh) | 一种增加骨密度、防治骨质疏松症的天然药物组合物 | |
CN102526444A (zh) | 一种补肾壮阳的中药组合物及其制备方法 | |
CN108524805A (zh) | 一种壮阳补肾的功能性组合物及其制备方法和应用 | |
US20180169071A1 (en) | Nutritional supplement composition | |
CN108633997A (zh) | 一种具有抗疲劳功能的保健羊奶粉及其制备方法 | |
CN103520302A (zh) | 一种沙棘叶抗疲劳胶囊及其制备方法 | |
CN104001157A (zh) | 一种防治骨质疏松症的复方制剂及其制备方法 | |
CN103451067B (zh) | 抗疲劳保健药酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
RJ01 | Rejection of invention patent application after publication |